ResoundingHealth
Search
  
Basic Drug Info
Drug Name:ZANTAC
Manufacturer:GlaxoSmithKline
Other Info:



Clinical Trials:


Indications and Usage

ZANTAC is indicated in:Short-term treatment of active duodenal ulcer.

Most patients heal within 4 weeks.

Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks.Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.

No placebo-controlled comparative studies have been carried out for periods of longer than 1 year.The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis).Short-term treatment of active, benign gastric ulcer.

Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated.

Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks.Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers.

Placebo-controlled studies have been carried out for 1 year.Treatment of GERD.

Symptomatic relief commonly occurs within 24 hours after starting therapy with ZANTAC 150 mg b.i.d.Treatment of endoscopically diagnosed erosive esophagitis.

Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ZANTAC 150 mg q.i.d.Maintenance of healing of erosive esophagitis.

Placebo-controlled trials have been carried out for 48 weeks.Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis.
Duodenal Ulcer -- A PEPTIC ULCER located in the DUODENUM.

Zollinger-Ellison syndrome -- A syndrome that is characterized by the triad of severe PEPTIC ULCER, hypersecretion of GASTRIC ACID, and GASTRIN-producing tumors of the PANCREAS or other tissue (GASTRINOMA). This syndrome may be sporadic or be associated with MULTIPLE ENDOCRINE NEOPLASIA TYPE 1.

Gastroesophageal reflux disease -- Retrograde flow of gastric juice (GASTRIC ACID) and/or duodenal contents (BILE ACIDS; PANCREATIC JUICE) into the distal ESOPHAGUS, commonly due to incompetence of the LOWER ESOPHAGEAL SPHINCTER. Gastric regurgitation is an extension of this process with retrograde flow into the PHARYNX or MOUTH.

Erosive esophagitis --

Heartburn -- Substernal pain or burning sensation, usually associated with regurgitation of gastric juice into the esophagus.

Contraindications
ZANTAC is contraindicated for patients known to have hypersensitivity to the drug or any of the ingredients (see PRECAUTIONS).
Hypersensitivity -- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.


This web-site is for informational purposes only and is not intended as a substitute for advice from your doctor. It should not to be used for self-diagnosis or treatment.